TCRT Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Alaunos Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 50.0% on the year before.
Last close Β· Oct 23, 2026
$2.28
25.0%Hi! I read Alaunos Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β50.0%
No. Sales fell 50.0% last year.
Does it make a profit?
β83,520.0%
No. It lost money last year.
Does profit turn into cash?
β59,340.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Alaunos Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 50.0% on the year before. Its operating margin was β84,500.0%, down 36,380.0Β pts: of every 100 in sales, about β84,500 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Alaunos Therapeutics, Inc. lost $4.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$3.0M in fiscal 2025, β59,340.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Alaunos Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Debt incl. finance leases | $24.1M | $16.8M | $0.0M | $0.0M | β |
| Debt / equity | 0.4x | 0.4x | 0.0x | 0.0x | β |
| Interest coverage | β65.2x | β11.1x | β17.8x | β | β |
| Current ratio | 4.9x | 2.2x | 4.2x | 4.0x | 2.4x |
| Quick ratio | 4.9x | 2.2x | 4.2x | 4.0x | 2.4x |
| Total assets | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M |
| Total liabilities | $36.8M | $26.4M | $2.0M | $0.7M | $0.8M |
| Shareholders' equity | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
| Net debt (β = net cash) | β$51.9M | β$22.3M | β$6.1M | β$1.1M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Alaunos Therapeutics, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 2 / 7 | β / 6 | β / 6 | 2 / 8 | 4 / 8 | 4 / 8 | 1 / 8 | 2 / 7 |
| Accruals ratio | β100.6% | 0.3% | β3.6% | β75.4% | β18.0% | β14.3% | β10.6% | 69.6% | 5.3% | β45.7% |
| Altman Z'' | β26.51 | β22.79 | β8.60 | β11.34 | β9.86 | β28.46 | β43.31 | β380.77 | β1,092.86 | β1,020.47 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $6.9M | $15.9M | $0.1M | β | $0.0M | $0.4M | $2.9M | $0.0M | $0.0M | $0.0M |
| Research and development | $158M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $0.4M | $1.4M |
| Operating income | β$165M | β$53.5M | β$53.9M | β$57.9M | β$80.4M | β$77.5M | β$35.1M | β$34.3M | β$4.8M | β$4.2M |
| Interest expense | β | β | β | β | β | $1.2M | $3.2M | $1.9M | $0.0M | β |
| Income tax | β | β | β | β | β | β | β | β | β | $0.0M |
| Net income | β$165M | β$54.3M | β$53.1M | β$118M | β$80.0M | β$78.8M | β$37.7M | β$4.7M | β$4.7M | β$4.2M |
| Net income to common | β$172M | β$73.3M | $137M | β$118M | β$80.0M | β$78.8M | β | β | β$4.7M | β$4.3M |
| Diluted EPS | β$1.32 | β$0.53 | $0.96 | β$0.70 | β$0.38 | β$0.37 | β$2.61 | β$21.97 | β$2.92 | β$2.20 |
| Diluted shares | 0.13B | 0.14B | 0.14B | 0.17B | 0.21B | 0.21B | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$58.3M | β$54.7M | β$49.5M | β$40.9M | β$57.0M | β$61.5M | β$29.2M | β$30.1M | β$5.0M | β$2.9M |
| Capital expenditure | $0.6M | $0.7M | $0.5M | $0.3M | $9.8M | $3.3M | $0.2M | $0.2M | $0.0M | $0.1M |
| Free cash flow | β$58.9M | β$55.4M | β$49.9M | β$41.1M | β$66.8M | β$64.8M | β$29.4M | β$30.3M | β$5.0M | β$3.0M |
| Depreciation and amortization | $0.3M | $0.4M | $0.6M | $0.6M | $1.1M | $2.6M | $2.8M | $2.3M | $0.0M | $0.0M |
| Stock-based compensation | $8.5M | $8.5M | $7.5M | $6.3M | $6.8M | $10.8M | $3.5M | $2.8M | $0.4M | $0.8M |
| Share buybacks | $0.0M | $0.0M | $1.6M | $0.7M | β | $0.0M | $0.0M | $0.0M | β | β |
| Dividends and buybacks | $0.0M | $0.0M | $1.6M | $0.7M | β | $0.0M | $0.0M | $0.0M | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $81.1M | $70.9M | $61.7M | $79.7M | $115M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Total debt | β | β | β | β | $0.0M | $24.1M | $16.8M | $0.0M | $0.0M | β |
| Current assets | $105M | $90.8M | $84.3M | $105M | $131M | $78.8M | $53.8M | $8.3M | $2.8M | $2.0M |
| Current liabilities | $15.8M | $20.9M | $9.5M | $12.5M | $18.4M | $16.0M | $24.2M | $2.0M | $0.7M | $0.8M |
| Property and equipment, net | $0.8M | $1.2M | $1.1M | $1.1M | $10.2M | $10.9M | $8.5M | $0.0M | $0.0M | $0.1M |
| Total assets | $106M | $106M | $95.1M | $109M | $146M | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M |
| Total liabilities | $58.3M | $58.4M | $9.5M | $14.1M | $22.4M | $36.8M | $26.4M | $2.0M | $0.7M | $0.8M |
| Shareholders' equity | β$77.3M | β$96.8M | $85.6M | $95.0M | $124M | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
| Margins | ||||||||||
| Operating margin | β2,409.4% | β336.4% | β36,921.9% | β | β | β19,484.7% | β1,201.4% | β685,340.0% | β48,120.0% | β84,500.0% |
| EBITDA margin | β2,405.1% | β334.1% | β36,528.1% | β | β | β18,832.2% | β1,107.0% | β639,040.0% | β48,100.0% | β84,360.0% |
| Net margin | β2,409.2% | β341.7% | β36,381.5% | β | β | β19,786.7% | β1,291.2% | β93,580.0% | β46,790.0% | β83,520.0% |
| FCF margin | β858.1% | β348.5% | β34,189.0% | β | β | β16,279.1% | β1,007.8% | β606,780.0% | β49,710.0% | β59,340.0% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β712.3% | β1,000.9% | β170.5% | β11,049.4% | β391.1% | β |
| Return on capital employed | β182.6% | β63.1% | β63.0% | β59.9% | β62.8% | β98.4% | β86.1% | β543.3% | β233.3% | β196.2% |
| Return on equity | β | β | β | β130.5% | β73.0% | β86.5% | β78.1% | β20.9% | β111.8% | β198.1% |
| Return on assets | β155.4% | β51.3% | β52.9% | β115.4% | β62.6% | β65.3% | β47.2% | β12.8% | β84.9% | β146.0% |
| Return on tangible equity | β | β | 160.4% | β124.0% | β64.5% | β135.6% | β97.9% | β74.2% | β226.8% | β198.9% |
| Growth | ||||||||||
| Revenue growth | β | 131.7% | β99.1% | β | β | β | 634.2% | β99.8% | 100.0% | β50.0% |
| EPS growth | β | β | β | β172.9% | β | β | β | β | β | β |
| Share count change | β | 5.0% | 4.9% | 16.9% | 24.8% | 2.3% | β93.2% | β89.0% | 0.1% | 21.7% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.4x | 0.4x | 0.0x | 0.0x | β |
| Interest coverage | β | β | β | β | β | β65.2x | β11.1x | β17.8x | β | β |
| Current ratio | 6.6x | 4.4x | 8.9x | 8.4x | 7.1x | 4.9x | 2.2x | 4.2x | 4.0x | 2.4x |
| Quick ratio | 6.6x | 4.4x | 8.9x | 8.4x | 7.1x | 4.9x | 2.2x | 4.2x | 4.0x | 2.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 8.0% | 4.6% | 314.4% | β | β | 834.9% | 7.4% | 3,940.0% | 0.0% | 1,960.0% |
| Stock comp / revenue | 123.2% | 53.2% | 5,160.3% | β | β | 2,707.0% | 120.7% | 56,000.0% | 4,350.0% | 15,920.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 2.0 | β | β | 2.0 | 4.0 | 4.0 | 1.0 | 2.0 |
| Altman Z'' | β26.5 | β22.8 | β8.6 | β11.3 | β9.9 | β28.5 | β43.3 | β380.8 | β1,092.9 | β1,020.5 |
| Accruals ratio | β100.6% | 0.3% | β3.6% | β75.4% | β18.0% | β14.3% | β10.6% | 69.6% | 5.3% | β45.7% |
Source: SEC EDGAR XBRL filings (CIK 0001107421). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
